Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | LPL | P06858 | 12/20 | 0.38 |
| ▸ | LIPG | Q9Y5X9 | 12/20 | 0.38 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.36 |
| ▸ | F11 | P03951 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31731068 | 0.84 | LPL (0.42) | FFAR1LPLLIPGDGAT1CA1 | |
| SCHEMBL31730936 | 0.80 | LPL (0.40) | FFAR1LPLLIPGDGAT1CA1 | |
| SCHEMBL17440882 | 0.74 | IRAK4 (0.45) | FFAR1LPLLIPGDGAT1IRAK4 | |
| SCHEMBL18041611 | 0.73 | LPL (0.44) | FFAR1LPLLIPGDGAT1F11 | |
| SCHEMBL20600818 | 0.72 | LPL (0.39) | FFAR1LPLLIPGDGAT1CA1 | |
| SCHEMBL17441312 | 0.70 | GABRA1 (0.40) | FFAR1LPLLIPGDGAT1IRAK4 | |
| SCHEMBL24366626 | 0.70 | LPL (0.40) | FFAR1LPLLIPGDGAT1F11 | |
| SCHEMBL18041526 | 0.70 | TGFBR1 (0.42) | FFAR1LPLLIPGDGAT1F11 | |
| SCHEMBL506215 | 0.69 | DGAT1 (0.47) | FFAR1LPLLIPGDGAT1F11 | |
| SCHEMBL17492388 | 0.69 | LPL (0.46) | FFAR1LPLLIPGF11CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250352549-A1 | SUBSTITUTED HETEROCYCLIC COMPOUND DERIVATIVES AND THEIR PHARMACEUTICAL USE | AVELOS THERAPEUTICS INC. (KR) | 2025-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250352549-A1 | SUBSTITUTED HETEROCYCLIC COMPOUND DERIVATIVES AND THEIR PHARMACEUTICAL USE | MAST1, MAST3, MAST4 | FFAR1 4149/4885LPL 4098/4885LIPG 1828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.